Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Evaluation of the Role of Plasma Procalcitonin in Prediction of Intra-amniotic Infection in Preterm Premature Rupture of Membrane

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02104791
Recruitment Status : Unknown
Verified April 2014 by Alaa Sayed Hassanin, Ain Shams Maternity Hospital.
Recruitment status was:  Enrolling by invitation
First Posted : April 4, 2014
Last Update Posted : April 4, 2014
Sponsor:
Information provided by (Responsible Party):
Alaa Sayed Hassanin, Ain Shams Maternity Hospital

Brief Summary:
It is hypothesized that the procalcitonin has a role to play in prediction of intra-amniotic subclinical infection.

Condition or disease Intervention/treatment
Intra-amniotic Subclinical Infection. Drug: procalcitonin

Detailed Description:

Study population

  • This study will be conducted at the department of Obstetrics and Gynecology recruiting pregnant women selected from the attendees of antenatal clinic, emergency department and from inpatient wards of Ain Shams University Maternity Hospital from Mars2014.
  • This study will include 100 pregnant women these cases will be divided into 2 groups:
  • Group 1: Healthy preterm Group: will include 50 pregnant females all at 24-34 weeks of gestational age .
  • Group 2: Preterm premature rupture of membrane Group: will include 50 pregnant females all at 24-34 weeks of gestational age

Layout table for study information
Study Type : Observational
Actual Enrollment : 100 participants
Observational Model: Case Control
Time Perspective: Retrospective
Official Title: Procalcitonin Has a Role to Play in Prediction of Intra-amniotic Subclinical Infection.
Study Start Date : May 2014
Estimated Primary Completion Date : May 2015

Group/Cohort Intervention/treatment
procalcitonin in blood
-Group 1: Healthy preterm Group: will include 50 pregnant females all at 24-34 weeks of gestational age .
Drug: procalcitonin
In patient with preterm premature rupture of membrane (PPROM) is the procalcitonin can be used to predict intra-amniotic subclinical infection?
Other Name: plasma

plasma of blood
-Group 2: Preterm premature rupture of membrane Group include 50 pregnant women
Drug: procalcitonin
In patient with preterm premature rupture of membrane (PPROM) is the procalcitonin can be used to predict intra-amniotic subclinical infection?
Other Name: plasma

procalcitonin,prematureruptureofmembrane in blood

Complete history including (special habits like smoking and alcohol taking, menstrual history especially LMP, medical diseases, past obstetric history including duration, mode of delivery for each pregnancy, and if there were fetal or maternal complications).

Physical examination including (general condition, height, weight, vital signs).-Ultrasound to execlude multiple pregnancies, IUFD and to confirm oligohydraminos in group2.

The venous blood samples will be taken for measuring of -Procalcitonin in mothors -CRP and WBCs in mothers to detect infection -CRP in neonates of mothers of group 2.

They will be asked for their permission and consent.

Drug: procalcitonin
In patient with preterm premature rupture of membrane (PPROM) is the procalcitonin can be used to predict intra-amniotic subclinical infection?
Other Name: plasma




Primary Outcome Measures :
  1. The correlation between procalcitonin level in PPROM and C-reactive protein level in neonates. [ Time Frame: one year ]
    The correlation between procalcitonin level in PPROM and C-reactive protein level in neonates


Secondary Outcome Measures :
  1. Procalcitonin. - C-reactive protein. - White blood cells count (total and diffrantiated). -C-reactive protein in neonates of groub 2. [ Time Frame: one year ]

    Procalcitonin.

    • C-reactive protein.
    • White blood cells count (total and diffrantiated).
    • C-reactive protein in neonates of groub 2.


Other Outcome Measures:
  1. Procalcitonin. - C-reactive protein. - White blood cells count (total and diffrantiated). -C-reactive protein in neonates of groub 2. [ Time Frame: one year ]

    Procalcitonin.

    • C-reactive protein.
    • White blood cells count (total and diffrantiated).
    • C-reactive protein in neonates of groub 2.


Biospecimen Retention:   Samples Without DNA
plasma


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   20 Years to 40 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population

Study population

  • This study will be conducted at the department of Obstetrics and Gynecology recruiting pregnant women selected from the attendees of antenatal clinic, emergency department and from inpatient wards of Ain Shams University Maternity Hospital from Mars2014.
  • This study will include 100 pregnant women these cases will be divided into 2 groups:
  • Group 1: Healthy preterm Group: will include 50 pregnant females all at 24-34 weeks of gestational age .
  • Group 2: Preterm premature rupture of membrane Group: will include 50 pregnant females all at 24-34 weeks of gestational age.
Criteria

Patients are with singleton pregnancies. Rupture of membranes will be diagnosed by history, sterile speculum examination to confirm fluid leakage from the cervical canal and ultrasound to confirm oligohydraminos.

Subclinical infection will be detected with laboratory indices (WBC count of ≥15, 000 c/mm3, CRP of ≥1 mg/dL) without any clinical symptoms and signs of infection as urinary tract infection in group 1 patients.

Women with multiple pregnancies. Clinical signs of infection as (fever,abdominal tendernes). Cervical dilatations of 2 cm or more. Maternal disease like diabetes or fetal complications like intra-uterine fetal death.

Inclusion Criteria:

-

Exclusion Criteria:

-


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02104791


Locations
Layout table for location information
Egypt
Ain Shams Maternity Hospital
Cairo, Egypt, 02
Sponsors and Collaborators
Ain Shams Maternity Hospital

Publications of Results:
Layout table for additonal information
Responsible Party: Alaa Sayed Hassanin, Lecturer, Ain Shams Maternity Hospital
ClinicalTrials.gov Identifier: NCT02104791     History of Changes
Other Study ID Numbers: MRCOG-1988
First Posted: April 4, 2014    Key Record Dates
Last Update Posted: April 4, 2014
Last Verified: April 2014
Keywords provided by Alaa Sayed Hassanin, Ain Shams Maternity Hospital:
Procalcitonin
intra-amniotic subclinical infection.
Additional relevant MeSH terms:
Layout table for MeSH terms
Infection
Communicable Diseases
Asymptomatic Infections
Asymptomatic Diseases
Disease Attributes
Pathologic Processes